Evaluating radiotherapy for head and neck tumors
Radiotherapy Treatments for Neoplasms in the Head and Neck Region
This study is testing how well different radiotherapy treatments work for people with tumors in their head and neck and how well patients can tolerate these treatments.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 4050 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | European Institute of Oncology Academic / other |
| Locations | 1 site (Milan) |
| Trial ID | NCT06335342 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the clinical and dosimetric aspects, tolerance, and effectiveness of radiotherapy treatments for neoplasms located in the head and neck region. It will collect data from patients undergoing radiotherapy for both primary and secondary tumors, focusing on treatment outcomes and patient tolerance. The study will analyze various treatment strategies established through multidisciplinary discussions, taking into account disease characteristics, patient preferences, and functional aspects. The goal is to identify the most effective treatment protocols based on collected data over time.
Who should consider this trial
Good fit: Ideal candidates include patients receiving radiotherapy for primary or secondary neoplasms in the head and neck region.
Not a fit: Patients undergoing radiotherapy for tumors located outside the head and neck region will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies for patients with head and neck neoplasms.
How similar studies have performed: Other studies have shown success in evaluating radiotherapy treatments for similar conditions, indicating that this approach is supported by existing research.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients treated with radiotherapy for curative, palliative, neo-adjuvant, and adjuvant purposes in the head and neck region include those with: * Primary bone tumors, * Primary soft tissue tumors, * Primary tumors of the cardio-circulatory system, * Primary tumors of the lymphatic system, * Primary tumors of the nervous system and skin, * Secondary metastases from various origins localized in that district. * Signed informed consent Exclusion Criteria: • Radiotherapy in districts other than the head and neck region
Where this trial is running
Milan
- European Institute of Oncology — Milan, Italy (Recruiting)
Study contacts
- Principal investigator: Barbara Alicja Jereczek — European Institute of Oncology
- Study coordinator: Barbara Alicja Jereczek
- Email: barbara.jereczek@ieo.it
- Phone: +39 02 57489326
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.